RE: Rabbit2 Jul 2020 21:27
Today's Times rubs our nose in it somewhat by quoting other Aim stocks in the Corona field where the SP has performed somewhat better -Avacta up 700 per cent since March, Genedrive a modest 1,500 per cent over the past six months, and Haydale up 51 per cent yesterday alone.
Recently Ygen has moved like the proverbial Italian tank- in reverse.
We are at the stage where LR has serious work to do to restore credibility of the company. Although delivering on pretty much most of the core-business targets within specified time-frames, after an initial spike following the corona plans in March, Mr Market has been fed a number of projects, but not supported by a single sum to indicate future projections.
With wonderful hindsight, it is no surprise the uncertainty has impacted the SP.
Just a few questions to contemplate:
is the number of directors top-heavy for a company of this size, and is some severe pruning overdue and merited?
Is it time to restate the Co. objectives if corona is to be a significant revenue generator going forward?
Just how many Coronas have we sold, who are we still in bed with, and can detailed future projections accompany the forthcoming results?
Will the Co. confirm if any nhs initial link has been a flop?
Where are we with the US- has the Co. passed through customs yet, with or without a mask, and are we selling yet?
Just how much has the cost base increased with recent recruiting and training?
Really, that's it for now, but much more yet unanswered.
Still remaining here, but a retrace upwards is sorely overdue.